Gilead Sciences, Inc.
GILD · Nasdaq
GILD · Nasdaq
Gilead Sciences is a biopharmaceutical company that develops and sells medicines, with its dominant commercial franchise in HIV treatment. The company also has products and research programs outside HIV, including areas referenced by recent coverage of multiple FDA approvals, although the supplied evidence does not quantify their individual contributions. Gilead sells primarily through prescription pharmaceutical channels to healthcare providers, patients, insurers, and government-related payers. It generated $29.4 billion of revenue and $8.5 billion of net income in fiscal 2025, compared with $28.8 billion of revenue and $0.5 billion of net income in fiscal 2024.
Gilead Sciences rose $0.30, or 0.21%, over the week, from $146.34 to $146.64. The move was not a steady advance: the stock climbed to $149.92 on September 1 and $151.22 on September 3 before giving back nearly all of those gains in the September 8 session, when it fell 2.89% to $146.64 on 6.1 million shares. The supplied evidence does not identify a company-specific announcement, earnings release, or guidance change explaining the reversal. Instead, the stock moved without a documented company catalyst, with trading concentrated around the sharp late-week decline. Articles discussing approvals, analyst views, and investment plans provide broader context but no clearly dated weekly trigger.
Gilead shares rose $2.36, or 1.59%, from $148.86 to $151.22 over the stated week. The stock first recovered from a $146.34 close on Monday, gained 2.45% on Tuesday to $149.92, slipped modestly Wednesday, and then added 1.08% Thursday. The most important company-specific catalyst was optimism surrounding accelerated FDA approval for an HDV treatment, while separate coverage highlighted FDA approval of Bixlenvo as a new single-tablet HIV option. Positive research framing, including a Zacks Strong Buy upgrade and reports describing Gilead as a quality dividend stock, supported sentiment. A reported sale of 15,000 shares by the CEO near $150 was a counterpoint, but did not prevent the late-week advance.
Gilead fell $0.44, or 0.30%, over the week, closing at $145.68 versus $146.12 on August 21. The stock rose $0.62 on Monday and another $2.03 on Tuesday, then eased $0.68 on Wednesday and added $0.77 on Thursday as investors focused on the European Commission’s Trodelvy-Keytruda approval and the expected FDA decision on Bixlenvo. Thursday’s FDA approval of once-daily Bixlenvo for virologically suppressed adults with HIV did not prevent a sharp Friday reversal: shares dropped $3.18, giving back the week’s gains. No negative company-specific announcement was supplied for Friday; a reported health-care ETF outflow that included GILD provided broader sector context.
Gilead rose $3.00, or 2.30%, from $130.21 to $133.21 over the week. The advance was volatile: shares gained $0.94 on Monday and jumped another $4.10 on Tuesday to $135.25, then gave back most of that move over the next two sessions, falling $3.49 on Wednesday and $0.90 on Thursday. Friday brought a $2.35 rebound to finish at the weekly high. Trading volume increased during the reversal, reaching 11.38 million shares on Wednesday. The supplied evidence does not identify a company-specific announcement, guidance change, or analyst action during the week, so the move appears driven by trading around recent strength and broader market factors that are not specified.
Gilead rose $0.93, or 0.69%, from $134.32 to $135.25, reversing a four-session slide that carried the stock to $130.21 by July 31. The main catalyst was anticipation of, and reporting around, second-quarter results on August 4: Gilead posted a 5.92% revenue surprise and a 4.53% earnings surprise despite reporting a quarterly loss, while revenue grew at a double-digit rate. The loss reflected more than $11 billion of acquired in-process research and development charges tied to recent acquisitions. The stock gained $4.10 on August 4, on volume of 10.1 million shares, recovering most of the prior decline; no separate market-wide driver was provided.
